JP7497159B2 - 慢性回腸嚢炎の治療のための方法 - Google Patents

慢性回腸嚢炎の治療のための方法 Download PDF

Info

Publication number
JP7497159B2
JP7497159B2 JP2019565281A JP2019565281A JP7497159B2 JP 7497159 B2 JP7497159 B2 JP 7497159B2 JP 2019565281 A JP2019565281 A JP 2019565281A JP 2019565281 A JP2019565281 A JP 2019565281A JP 7497159 B2 JP7497159 B2 JP 7497159B2
Authority
JP
Japan
Prior art keywords
antibody
weeks
pouchitis
human subject
dose
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2019565281A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020521761A5 (enExample
JP2020521761A (ja
Inventor
ロザリオ，マリア
デイビッド ローレンス スミス，マイケル
タン，ハウ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Millennium Pharmaceuticals Inc
Original Assignee
Millennium Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Millennium Pharmaceuticals Inc filed Critical Millennium Pharmaceuticals Inc
Publication of JP2020521761A publication Critical patent/JP2020521761A/ja
Publication of JP2020521761A5 publication Critical patent/JP2020521761A5/ja
Priority to JP2024022711A priority Critical patent/JP2024069230A/ja
Application granted granted Critical
Publication of JP7497159B2 publication Critical patent/JP7497159B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2839—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Endocrinology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP2019565281A 2017-05-26 2018-05-26 慢性回腸嚢炎の治療のための方法 Active JP7497159B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2024022711A JP2024069230A (ja) 2017-05-26 2024-02-19 慢性回腸嚢炎の治療のための方法

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762511832P 2017-05-26 2017-05-26
US62/511,832 2017-05-26
PCT/IB2018/053760 WO2018215995A1 (en) 2017-05-26 2018-05-26 Methods for the treatment of chronic pouchitis

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2024022711A Division JP2024069230A (ja) 2017-05-26 2024-02-19 慢性回腸嚢炎の治療のための方法

Publications (3)

Publication Number Publication Date
JP2020521761A JP2020521761A (ja) 2020-07-27
JP2020521761A5 JP2020521761A5 (enExample) 2021-07-26
JP7497159B2 true JP7497159B2 (ja) 2024-06-10

Family

ID=64395342

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2019565281A Active JP7497159B2 (ja) 2017-05-26 2018-05-26 慢性回腸嚢炎の治療のための方法
JP2024022711A Pending JP2024069230A (ja) 2017-05-26 2024-02-19 慢性回腸嚢炎の治療のための方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2024022711A Pending JP2024069230A (ja) 2017-05-26 2024-02-19 慢性回腸嚢炎の治療のための方法

Country Status (10)

Country Link
US (2) US20200087401A1 (enExample)
EP (1) EP3630184A4 (enExample)
JP (2) JP7497159B2 (enExample)
KR (1) KR20200011457A (enExample)
AU (1) AU2018274749B2 (enExample)
BR (1) BR112019024875A2 (enExample)
CA (1) CA3065000A1 (enExample)
IL (1) IL270819A (enExample)
MX (1) MX2019014090A (enExample)
WO (1) WO2018215995A1 (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20170327584A1 (en) 2014-11-26 2017-11-16 Millennium Pharmaceuticals, Inc. Vedolizumab for the Treatment of Fistulizing Crohn's Disease
WO2023163883A1 (en) * 2022-02-22 2023-08-31 First Wave BioPharma, Inc. Compositions and methods for treating pouchitis
TW202504919A (zh) 2023-05-30 2025-02-01 美商派拉岡醫療公司 α4β7整合素抗體組合物及使用方法

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2014514346A (ja) 2011-05-02 2014-06-19 ミレニアム ファーマシューティカルズ， インコーポレイテッド 抗α４β７抗体のための製剤

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6551593B1 (en) * 1995-02-10 2003-04-22 Millennium Pharmaceuticals, Inc. Treatment of Inflammatory bowel disease by inhibiting binding and/or signalling through α 4 β 7 and its ligands and madcam
WO2016105572A1 (en) * 2014-12-24 2016-06-30 Millennium Pharmaceuticals, Inc. PREDICTING OUTCOME OF TREATMENT WITH AN ANTI-α4β7 INTEGRIN ANTIBODY

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2014514346A (ja) 2011-05-02 2014-06-19 ミレニアム ファーマシューティカルズ， インコーポレイテッド 抗α４β７抗体のための製剤

Non-Patent Citations (7)

* Cited by examiner, † Cited by third party
Title
ClinicalTrials.gov Archive NCT02620046 on 2017_05_24，2017年05月24日，Retrieved from the Internet: ＵＲＬ，https://clinicaltrials.gov/ct2/history/NCT02790138
ClinicalTrials.gov Archive NCT02790138 on 2017_05_04，2017年05月04日，Retrieved from the Internet: ＵＲＬ，https://clinicaltrials.gov/ct2/history/NCT02790138
Inflammatory Bowel Diseases，2017年01月，Volume 23, Issue 1， Pages E5-E6
Int J Colorectal Dis，2017年01月，32，597-598
医学のあゆみ，2016年，Vol.265, No.10，p.1107-1111
日本大腸肛門病会誌，2011年，６４，８３４－８４１
臨牀と研究，2014年，９１巻８号，1017-1021

Also Published As

Publication number Publication date
KR20200011457A (ko) 2020-02-03
AU2018274749A1 (en) 2019-12-19
EP3630184A1 (en) 2020-04-08
EP3630184A4 (en) 2021-03-17
WO2018215995A1 (en) 2018-11-29
IL270819A (en) 2020-01-30
US20230043949A1 (en) 2023-02-09
BR112019024875A2 (pt) 2020-06-16
JP2024069230A (ja) 2024-05-21
RU2019143659A3 (enExample) 2021-10-08
AU2018274749B2 (en) 2025-05-22
MX2019014090A (es) 2021-01-08
RU2019143659A (ru) 2021-06-28
CA3065000A1 (en) 2018-11-29
US20200087401A1 (en) 2020-03-19
JP2020521761A (ja) 2020-07-27

Similar Documents

Publication Publication Date Title
JP7579227B2 (ja) 瘻孔を伴うクローン病の治療用ベドリズマブ
Allez et al. Report of the ECCO pathogenesis workshop on anti-TNF therapy failures in inflammatory bowel diseases: definitions, frequency and pharmacological aspects
US12246064B2 (en) Method of treating Crohn's disease by administering a triple combination therapy of anti-integrin antibody, adalimumab and methotrexate
JP2024069230A (ja) 慢性回腸嚢炎の治療のための方法
JP2025118642A (ja) 移植片対宿主病の処置または予防の方法
JP2019508448A (ja) 移植片対宿主病予防の方法
US20240182581A1 (en) Methods for the treatment of chronic pouchitis
US20230279095A1 (en) Methods and Treatment for Adult-Onset Still's Disease and Systemic-Onset Juvenile Idiopathic Arthritis Involving Antibodies to IL-18
RU2822135C2 (ru) Способы лечения хронического резервуарного илеита
US20250122289A1 (en) Methods of treating or preventing graft versus host disease
WO2025099576A1 (en) Compositions and methods for treating rheumatoid arthritis
WO2025177055A1 (en) Combination therapy for treating inflammatory bowel disease
TW202515615A (zh) 治療發炎性腸病之方法
WO2025229563A1 (en) Methods of treating inflammatory bowel disease
US20240158522A1 (en) Methods of Treating Ulcerative Colitis with Anti-LIGHT Antibodies
KR20240134909A (ko) Il-18에 대한 항체를 포함하는 성인-발병성 스틸병 및 전신-발병성 소아 특발성 관절염에 대한 방법 및 치료
IL322944A (en) Methods for treating melanoma using anti-CTLA4 antibody
TW202325730A (zh) 涉及ｉｌ－１８抗體之成人史迪爾氏症（ｓｔｉｌｌ＇ｓ ｄｉｓｅａｓｅ）及全身性幼年特發性關節炎之方法及治療

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210526

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20210526

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20220524

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20220817

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20221018

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20221124

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20230124

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20230418

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20230614

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230724

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20231017

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240219

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20240418

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20240514

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20240529

R150 Certificate of patent or registration of utility model

Ref document number: 7497159

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150